🇺🇸 FDA
Patent

US 10435677

Genetically modified human cell with a corrected mutant sickle cell mutation

granted A61KA61K35/28A61K40/10

Quick answer

US patent 10435677 (Genetically modified human cell with a corrected mutant sickle cell mutation) held by Sangamo Therapeutics, Inc. expires Mon Oct 03 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Sangamo Therapeutics, Inc.
Grant date
Tue Oct 08 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 03 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
9
CPC classes
A61K, A61K35/28, A61K40/10, A61K40/40, A61K48/005